|
|
Volumn 103, Issue 6, 2011, Pages 458-460
|
|
Avastin's uncertain future in breast cancer treatment.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
TUMOR MARKER;
ARTICLE;
BLOOD;
BREAST TUMOR;
CLINICAL TRIAL (TOPIC);
DRUG APPROVAL;
EUROPE;
EVIDENCE BASED MEDICINE;
FEMALE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
INTERNATIONAL COOPERATION;
PATIENT SELECTION;
SURVIVAL;
TREATMENT FAILURE;
TREATMENT OUTCOME;
UNITED STATES;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
EUROPE;
EVIDENCE-BASED MEDICINE;
FEMALE;
HUMANS;
INTERNATIONAL COOPERATION;
PATIENT SELECTION;
SURVIVAL ANALYSIS;
TREATMENT FAILURE;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 79955708510
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djr088 Document Type: Article |
|
Times cited : (8)
|
|
References (0)
|
